Shots: Multiple Sclerosis affects over 2.8M people globally. Despite several tech infusions in MS research, the exact cause of the condition remains unknown Recently, Metabolon, known for providing metabolomics solutions joined hands with the Division of Psychological Medicine and Clinical Neuroscience (DPMCN) at Cardiff University to discover new biomarkers to expedite the understanding and treatment…
Shots: Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…
Shots:Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted PanelHe also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurementsThe interview highlights how Metabolon’s mission to deliver…
Shots:Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer The interview gives a profound understanding…
PharmaShots had its third interview for the “Spotlight- Company of the Month- Metabolon’’. The interview was with Rohan (Ro) F. Hastie, President & CEO at Metabolon where he shared insights from the journey, products, solutions, technologies, and upcoming plans of Metabolon. Metabolon develops analytical methods and software for biomarker discovery by using metabolomics. The company…
Shots:Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…

